12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Folotyn pralatrexate regulatory update

The European Medicines Agency (EMA) accepted for filing an MAA from Allos for Folotyn pralatrexate to treat relapsed or...

Read the full 75 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >